STAT3α is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone

Endocrinology

Volumn 151, Issue 9, 2010, Pages 4133-4145

  Tang, Jian Zhong ^a   Kong, Xiang Jun ^c   Banerjee, Arindam ^a   Muniraj, Nethaji ^a   Pandey, Vijay ^a   Steiner, Michael ^a   Perry, Jo K ^a   Zhu, Tao ^c   Liu, Dong Xu ^a   Lobie, Peter E ^a,b,d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HUMAN GROWTH HORMONE; JANUS KINASE 2; JSI 124; SMALL INTERFERING RNA; STAT3 PROTEIN; STAT3ALPHA PROTEIN; UNCLASSIFIED DRUG; CUCURBITACIN I; DELTA HGHR; DELTA-HGHR; MEMBRANE PROTEIN; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; XENOGRAFT; ANIMAL; CANCER INVASION; CELL MOTION; DRUG EFFECT; ENDOMETRIUM TUMOR; EXPERIMENTAL NEOPLASM; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; AUTOCRINE COMMUNICATION; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MEMBRANE PROTEINS; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; TRITERPENES;

EID: 77956020768     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0273     Document Type: Article

References (76)

1. Berrena Medel NI, Bansal S, Miller DS, Wright JD, Herzog TJ 2009 Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother 10:1939-1951
2. Temkin SM, Fleming G 2009 Current treatment of metastatic endometrial cancer. Cancer Control 16:38-45
3. Ray M, Fleming G 2009 Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 36:145-154
4. Zhu T, Goh EL, Graichen R, Ling L, Lobie PE 2001 Signal transduction via the growth hormone receptor. Cell Signal 13:599-616 (Pubitemid 32734097)
5. Liu N, Mertani HC, Norstedt G, Törnell J, Lobie PE 1997 Mode of the autocrine/paracrine mechanism of growth hormone action. Exp Cell Res 237:196-206
6. Sbracia M, Scarpellini F, Poverini R, Alò PL, Rossi G, Di Tondo U 2004 Immunohistochemical localization of the growth hormone in human endometrium and decidua. Am J Reprod Immunol 51:112-116 (Pubitemid 38239736)
7. Slater M, Cooper M, Murphy CR 2006 Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochem 108:13-18
8. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A 2007 Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 107:58-65
9. Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM, Wu ZS, Mitchell MD, Zhu T, Lobie PE 2008 Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 149:3909-3919
10. Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, Armatis P, Zarandi M, Varga JL, Halmos G 2005 Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 90:3614-3621 (Pubitemid 41014334)
11. Schally AV, Varga JL 2006 Antagonists of growth hormone-releasing hormone in oncology. Comb Chem High Throughput Screen 9:163-170
12. Al Zaid Siddiquee K, Turkson J 2008 STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18:254-267
13. Kim DJ, Chan KS, Sano S, Digiovanni J 2007 Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog 46:725-731
14. Wang Y, Morella KK, Ripperger J, Lai CF, Gearing DP, Fey GH, Campos SP, Baumann H 1995 Receptors for interleukin-3 (IL-3) and growth hormone mediate an IL-6-type transcriptional induction in the presence of JAK2 or STAT3. Blood 86:1671-1679
15. Han Y, Leaman DW, Watling D, Rogers NC, Groner B, Kerr IM, Wood WI, Stark GR 1996 Participation of JAK and STAT proteins in growth hormone-induced signaling. J Biol Chem 271:5947-5952
16. Campbell GS, Meyer DJ, Raz R, Levy DE, Schwartz J, Carter-Su C 1995 Activation of acute phase response factor (APRF)/Stat3 transcription factor by growth hormone. J Biol Chem 270:3974-3979
17. Jin H, Lanning NJ, Carter-Su C 2008 JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma Cells. Mol Endocrinol 22:1825-1841
18. Hosui A, Kimura A, Yamaji D, Zhu BM, Na R, Hennighausen L 2009 Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation. J Exp Med 206:819-831
19. Chakraborty A, White SM, Schaefer TS, Ball ED, Dyer KF, Tweardy DJ 1996 Granulocyte colony-stimulating factor activation of Stat3α and Stat3β in immature normal and leukemic human myeloid cells. Blood 88:2442-2449 (Pubitemid 26327492)
20. Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JA, Lammers JW, Koenderman L, de Groot RP 1996 STAT3β, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem 271:13221-13227
21. Wen Z, Zhong Z, Darnell Jr JE 1995 Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82:241-250
22. Mitchell TJ, John S 2005 Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 114:301-312 (Pubitemid 40314803)
23. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell Jr JE 1999 Stat3 as an oncogene. Cell 98:295-303
24. Gritsko T, Williams A, Turkson J, Kaneko S, BowmanT, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R 2006 Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12:11-19
25. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J 2007 Constitutively activated stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin B6. Mol Cell Biol 27:4444-4453
26. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC 2007 Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via PP-regulation of TWIST gene expression. Cancer Res 67:9066-9076
27. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K 2003 Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319-329
28. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE 2009 Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 114:121-127
29. Cymbaluk A, Chudecka-Glaz A, Rzepka-Górska I 2008 Leptin levels in serum depending on body mass index in patients with endometrial hyperplasia and cancer. Eur J Obstet Gynecol Reprod Biol 136:74-77
30. Sharma D, Saxena NK, Vertino PM, Anania FA 2006 Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13:629-640 (Pubitemid 43886682)
31. Carino C, Olawaiye AB, Cherfils S, Serikawa T, Lynch MP, Rueda BR, Gonzalez RR 2008 Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells. Int J Cancer 123:2782-2790
32. Engelsen IB, Akslen LA, Salvesen HB 2009 Biologic markers in endometrial cancer treatment. APMIS 117:693-707
33. Catalano RD, Johnson MH, Campbell EA, Charnock-Jones DS, Smith SK, Sharkey AM 2005 Inhibition of Stat3 activation in the endometrium prevents implantation: a nonsteroidal approach to contraception. Proc Natl Acad Sci USA 102:8585-8590
34. Bansal N, Yendluri V, Wenham RM 2009 The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16:8-13
35. Lin J, Tang H, Jin X, Jia G, Hsieh JT 2002 p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene 21:3082-3088
36. Proietti CJ, Rosemblit C, Beguelin W, Rivas MA, Diaz Flaqué MC, Charreau EH, Schillaci R, Elizalde PV 2009 Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol 29:1249-1265
37. Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, Cheng G, Hall BM, Lin J 2007 Stat3 activation in human endometrial and cervical cancers. Br J Cancer 96:591-599
38. Mohankumar KM, Perry JK, Kannan N, Kohno K, Gluckman PD, Emerald BS, Lobie PE 2008 Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1-stimulated oncogenic transformation of the immortalized human mammary epithelial cell. Endocrinology 149:2219-2229
39. Brunet-Dunand SE, Vouyovitch C, Araneda S, Pandey V, Vidal LJ, Print C, Mertani HC, Lobie PE, Perry JK 2009 Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150:1341-1352
40. Tang JZ, Zuo ZH, Kong XJ, Steiner M, Yin Z, Perry JK, Zhu T, Liu DX, Lobie PE 2010 Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology 151:43-55
41. Dawson CW, Young LS 2001 In vitro assays to study epithelial cell growth. Methods Mol Biol 174:165-172
42. Pötter E, Braun S, Lehmann U, Brabant G 2001 Molecular cloning of a functional promoter of the human plakoglobin gene. Eur J Endocrinol 145:625-633 (Pubitemid 33061909)
43. Wood TJ, Sliva D, Lobie PE, Goullieux F, Mui AL, Groner B, Norstedt G, Haldosén LA 1997 Specificity of transcription enhancement via the STAT responsive element in the serine protease inhibitor 2.1 promoter. Mol Cell Endocrinol 130:69-81
44. Yuan J, Wegenka UM, Lütticken C, Buschmann J, Decker T, Schindler C, Heinrich PC, Horn F 1994 The signalling pathways of interleukin-6 and γ interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol Cell Biol 14:1657-1668
45. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
46. van der Lely AJ, Kopchick JJ 2006 Growth hormone receptor antagonists. Neuroendocrinology 83:264-268
47. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM 2003 Discovery of JSI-124 (Cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63:1270-1279
48. Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z, Zhang J 2008 JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment. Cancer Biol Ther 7:1243-1249
49. Zhu T, Ling L, Lobie PE 2002 Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity. GH activation of Ral and phospholipase D is Src-dependent. J Biol Chem 277:45592-45603 (Pubitemid 36159170)
50. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE 2004 Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA 101:15166-15171
51. Hanahan D, Weinberg RA 2000 The hallmarks of cancer. Cell 100:57-70
52. Hotulainen P, Lappalainen P 2006 Stress fibers are generated by two distinct actin assembly mechanisms in motile cells. J Cell Biol 173:383-394
53. Shafiei F, Rahnama F, Pawella L, Mitchell MD, Gluckman PD, Lobie PE 2008 DNMT3A and DNMT3B mediate autocrine hGH repression of plakoglobin gene transcription and consequent phenotypic conversion of mammary carcinoma cells. Oncogene 27:2602-2612
54. Prat J 2004 Prognostic parameters of endometrial carcinoma. Hum Pathol 35:649-662
55. Lin J, Jin X, Rothman K, Lin HJ, Tang H, Burke W 2002 Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Cancer Res 62:376-380
56. Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, Van Waes C, Chen Z 2008 A signal network involving coactivated NF-κB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122:1987-1998
57. Yaginuma Y, Westphal H 1991 Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 51:6506-6509
58. Albitar L, Laidler LL, Abdallah R, Leslie KK 2005 Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors. Mol Cancer Ther 4:1891-1899 (Pubitemid 43056972)
59. Battle TE, Frank DA 2002 The role of STATs in apoptosis. Curr Mol Med 2:381-392
60. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschläger P, Schütz A, Halbhuber KJ, Friedrich K 2005 Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7:545-555
61. Yu H, Pardoll D, Jove R 2009 STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809
62. Ferrara N 2010 Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21:21-26
63. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H 2002 Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008
64. Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, Kujawski M, Kay H, Cress WD, Jove R, Yu H 2008 Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1α RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 6:1099-1105
65. Yu H, Kortylewski M, Pardoll D 2007 Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51 (Pubitemid 46020826)
66. Lieblein JC, Ball S, Hutzen B, Sasser AK, Lin HJ, Huang TH, Hall BM, Lin J 2008 STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer 8:302
67. Rivat C, Christine R, Rodrigues S, Sylvie R, Bruyneel E, Erik B, Piétu G, Geneviève P, Robert A, Amélie R, Redeuilh G, Gérard R, Bracke M, Marc B, Gespach C, Christian G, Attoub S, Samir A 2005 Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)- and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 65:195-202
68. Kaspar M, Zardi L, Neri D 2006 Fibronectin as target for tumor therapy. Int J Cancer 118:1331-1339
69. Zhang F, Li C, Halfter H, Liu J 2003 Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 22:894-905
70. Rahnama F, Thompson B, Steiner M, Shafiei F, Lobie PE, Mitchell MD 2009 Epigenetic regulation of E-cadherin controls endometrial receptivity. Endocrinology 150:1466-1472
71. Kim YT, Choi EK, Kim JW, Kim DK, Kim SH, Yang WI 2002 Expression of E-cadherin and α-, β-, γ-catenin proteins in endometrial carcinoma. Yonsei Med J 43:701-711
72. Moreno-Bueno G, Hardisson D, Sarrió D, Sánchez C, Cassia R, Prat J, Herman JG, Esteller M, Matias-Guiu X, Palacios J 2003 Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 199:471-478
73. Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T 1997 Suppression of E-cadherin and α- and β-catenin mRNA expression in the metastatic lesions of gynecological cancers. Eur J Gynaecol Oncol 18:484-487 (Pubitemid 27519415)
74. Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA 2006 STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood 108:1058-1064
75. Holland CM, Day K, Evans A, Smith SK 2003 Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 89:891-898
76. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen Jr CN, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK 2007 Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13:7487-7495